Summary
11.63 0.12(1.04%)06/27/2024
Regenxbio Inc (RGNX)
Regenxbio Inc (RGNX)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years | All Time |
| 1.13 | -2.02 | -18.36 | -46.94 | -38.27 | -41.02 | -81.97 | -15.42 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
| Trading Data | ||
| Close | 11.63 | |
| Open | 11.55 | |
| High | 11.90 | |
| Low | 11.34 | |
| Volume | 373,125 | |
| Change | 0.13 | |
| Change % | 1.13 | |
| Avg Volume (20 Days) | 416,930 | |
| Volume/Avg Volume (20 Days) Ratio | 0.89 | |
| 52 Week Range | 11.34 - 27.16 | |
| Price vs 52 Week High | -57.18% | |
| Price vs 52 Week Low | 2.56% | |
| Range | 0.69 | |
| Gap Up/Down | -0.67 | |
Fundamentals | ||
| Market Capitalization (Mln) | 576 | |
| EBIDTA | -87,438,000 | |
| PE Ratio | 0.0000 | |
| PEG Ratio | 0.2600 | |
| WallStreet Target Price | 62.00 | |
| Book Value | 10.7930 | |
| Earnings Per Share | -5.1690 | |
| EPS Estimate Current Quarter | -1.0800 | |
| EPS Estimate Next Quarter | 0.9000 | |
| EPS Estimate Current Year | 2.3900 | |
| EPS Estimate Next Year | -3.6900 | |
| Diluted EPS (TTM) | -5.1690 | |
| Revenues | ||
| Profit Marging | -2.2808 | |
| Operating Marging (TTM) | -2.2254 | |
| Return on asset (TTM) | -0.1931 | |
| Return on equity (TTM) | -0.4844 | |
| Revenue TTM | 93,137,000 | |
| Revenue per share TTM | 2.2660 | |
| Quarterly Revenue Growth (YOY) | -0.6890 | |
| Quarterly Earnings Growth (YOY) | 0.0000 | |
| Gross Profit (TTM) | -47,441,000 | |
| Dividends | ||
| Dividend Share | 0.0000 | |
| Dividend Yield | ||
| Valuations | ||
| Trailing PE | 0.0000 | |
| Forward PE | 0.0000 | |
| Price Sales (TTM) | 0.0000 | |
| Price Book (MRQ) | 2.9680 | |
| Revenue Enterprise Value | 11.9697 | |
| EBITDA Enterprise Value | 0.0000 | |
| Shares | ||
| Shares Outstanding | 42,769,200 | |
| Shares Float | 37,261,389 | |
| Shares Short | 0 | |
| Shares Short (Prior Month) | 0 | |
| Shares Ratio | 0.00 | |
| Short Outstanding (%) | 0.00 | |
| Short Float (%) | 0.00 | |
| Insider (%) | 12.46 | |
| Institutions (%) | 85.94 | |
06/25 05:35 EST - zacks.com
Regenxbio (RGNX) Soars 6.4%: Is Further Upside Left in the Stock?
Regenxbio (RGNX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Regenxbio (RGNX) Soars 6.4%: Is Further Upside Left in the Stock?
Regenxbio (RGNX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
06/24 12:56 EST - investorplace.com
7 Biotech Stocks to Buy on the Dip: June 2024
Fundamentally, the biotechnology sphere enjoys a powerful catalyst: wealth without health means nothing. Yes, it's important to save money and invest for the future.
7 Biotech Stocks to Buy on the Dip: June 2024
Fundamentally, the biotechnology sphere enjoys a powerful catalyst: wealth without health means nothing. Yes, it's important to save money and invest for the future.
06/24 07:05 EST - prnewswire.com
REGENXBIO Announces Expansion of AFFINITY DUCHENNE® Trial to Include a New Cohort of Younger Patients
Company to begin enrollment of patients aged 1-3 years Expects data from younger cohort to be part of pivotal plans and BLA filing for broad label End-of-Phase II meeting with FDA scheduled for late July to finalize pivotal program design Based on recent commercial landscape, confirmed accelerated approval pathway remains available given ongoing unmet need and RGX-202 differentiated design Remains on track to initiate pivotal trial in late Q3 to early Q4 2024 The next potential therapy to become available for Duchenne patients ROCKVILLE, Md., June 24, 2024 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it initiated enrollment in a new cohort of patients ages 1-3 in its Phase I/II AFFINITY DUCHENNE® trial to evaluate the safety and efficacy of RGX-202 in boys with Duchenne muscular dystrophy (Duchenne).
REGENXBIO Announces Expansion of AFFINITY DUCHENNE® Trial to Include a New Cohort of Younger Patients
Company to begin enrollment of patients aged 1-3 years Expects data from younger cohort to be part of pivotal plans and BLA filing for broad label End-of-Phase II meeting with FDA scheduled for late July to finalize pivotal program design Based on recent commercial landscape, confirmed accelerated approval pathway remains available given ongoing unmet need and RGX-202 differentiated design Remains on track to initiate pivotal trial in late Q3 to early Q4 2024 The next potential therapy to become available for Duchenne patients ROCKVILLE, Md., June 24, 2024 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it initiated enrollment in a new cohort of patients ages 1-3 in its Phase I/II AFFINITY DUCHENNE® trial to evaluate the safety and efficacy of RGX-202 in boys with Duchenne muscular dystrophy (Duchenne).
06/18 07:05 EST - prnewswire.com
REGENXBIO Announces Successful Pre-BLA Meeting with FDA to Support Accelerated Approval Pathway for RGX-121 for the Treatment of MPS II
Aligned with FDA on content of BLA and plans for submission: Submission of a rolling BLA using the accelerated approval pathway expected to start in Q3 2024 Confirmatory trial expected to begin in H2 2025 FDA confirmed RGX-121 commercial bulk drug is comparable to clinical material Positive biomarker, neurocognitive and systemic data will be part of BLA submission ROCKVILLE, Md. , June 18, 2024 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it completed a successful Pre-Biologics License Application (BLA) meeting for RGX-121 for the treatment Mucopolysaccharidosis Type II (MPS II), where it finalized details of its BLA with the U.S. Food and Drug Administration (FDA).
REGENXBIO Announces Successful Pre-BLA Meeting with FDA to Support Accelerated Approval Pathway for RGX-121 for the Treatment of MPS II
Aligned with FDA on content of BLA and plans for submission: Submission of a rolling BLA using the accelerated approval pathway expected to start in Q3 2024 Confirmatory trial expected to begin in H2 2025 FDA confirmed RGX-121 commercial bulk drug is comparable to clinical material Positive biomarker, neurocognitive and systemic data will be part of BLA submission ROCKVILLE, Md. , June 18, 2024 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it completed a successful Pre-Biologics License Application (BLA) meeting for RGX-121 for the treatment Mucopolysaccharidosis Type II (MPS II), where it finalized details of its BLA with the U.S. Food and Drug Administration (FDA).
06/12 07:05 EST - prnewswire.com
REGENXBIO Announces Leadership Transition
Curran Simpson, Chief Operating Officer, Appointed as President and CEO Co-Founder Kenneth T. Mills to Step Down as President and CEO; Named Chairman of the Board ROCKVILLE, Md.
REGENXBIO Announces Leadership Transition
Curran Simpson, Chief Operating Officer, Appointed as President and CEO Co-Founder Kenneth T. Mills to Step Down as President and CEO; Named Chairman of the Board ROCKVILLE, Md.
06/10 23:55 EST - seekingalpha.com
Regenxbio: Transforming Gene Therapy With Innovative AAV Treatments, Strong Buy
REGENXBIO develops AAV therapies using its proprietary NAV platform, offering one-dose treatments targeting disease root causes. The company's pipeline includes promising candidates for age-related macular degeneration, Duchenne muscular dystrophy, and Hunter syndrome. ABBV-RGX-314, RGX-202, and RGX-121 are key pipeline candidates targeting significant markets with promising clinical data.
Regenxbio: Transforming Gene Therapy With Innovative AAV Treatments, Strong Buy
REGENXBIO develops AAV therapies using its proprietary NAV platform, offering one-dose treatments targeting disease root causes. The company's pipeline includes promising candidates for age-related macular degeneration, Duchenne muscular dystrophy, and Hunter syndrome. ABBV-RGX-314, RGX-202, and RGX-121 are key pipeline candidates targeting significant markets with promising clinical data.
06/05 07:05 EST - prnewswire.com
REGENXBIO to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
ROCKVILLE, Md. , June 5, 2024 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it will participate in the Goldman Sachs 45th Annual Global Healthcare Conference on Wednesday, June 12, 2024.
REGENXBIO to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
ROCKVILLE, Md. , June 5, 2024 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it will participate in the Goldman Sachs 45th Annual Global Healthcare Conference on Wednesday, June 12, 2024.
05/10 07:05 EST - prnewswire.com
REGENXBIO to Participate in Upcoming Investor Conferences
ROCKVILLE, Md. , May 10, 2024 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it will participate in the following upcoming investor conferences: BofA Securities Health Care Conference 2024 Fireside Chat: Wednesday, May 15, 2024 at 2:20 p.m.
REGENXBIO to Participate in Upcoming Investor Conferences
ROCKVILLE, Md. , May 10, 2024 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it will participate in the following upcoming investor conferences: BofA Securities Health Care Conference 2024 Fireside Chat: Wednesday, May 15, 2024 at 2:20 p.m.
05/08 21:42 EST - seekingalpha.com
REGENXBIO Inc. (RGNX) Q1 2024 Earnings Call Transcript
REGENXBIO Inc. (NASDAQ:RGNX ) Q1 2024 Earnings Conference Call May 8, 2024 4:30 PM ET Company Participants Patrick Christmas – Chief Legal Officer Ken Mills – Chief Executive Officer Curran Simpson – Chief Operating Officer Vit Vasista – Chief Financial Officer Conference Call Participants Gena Wang – Barclays Annabel Samimy – Stifel Brian Skorney – Baird Luca Issi – RBC Capital Daniil Gataulin – Chardan Operator Good day and thank you for standing by. Welcome to REGENXBIO's First Quarter 2024 Earnings Conference Call.
REGENXBIO Inc. (RGNX) Q1 2024 Earnings Call Transcript
REGENXBIO Inc. (NASDAQ:RGNX ) Q1 2024 Earnings Conference Call May 8, 2024 4:30 PM ET Company Participants Patrick Christmas – Chief Legal Officer Ken Mills – Chief Executive Officer Curran Simpson – Chief Operating Officer Vit Vasista – Chief Financial Officer Conference Call Participants Gena Wang – Barclays Annabel Samimy – Stifel Brian Skorney – Baird Luca Issi – RBC Capital Daniil Gataulin – Chardan Operator Good day and thank you for standing by. Welcome to REGENXBIO's First Quarter 2024 Earnings Conference Call.
05/08 18:40 EST - zacks.com
Regenxbio (RGNX) Reports Q1 Loss, Lags Revenue Estimates
Regenxbio (RGNX) came out with a quarterly loss of $1.38 per share versus the Zacks Consensus Estimate of a loss of $1.28. This compares to loss of $1.53 per share a year ago.
Regenxbio (RGNX) Reports Q1 Loss, Lags Revenue Estimates
Regenxbio (RGNX) came out with a quarterly loss of $1.38 per share versus the Zacks Consensus Estimate of a loss of $1.28. This compares to loss of $1.53 per share a year ago.
05/08 16:05 EST - prnewswire.com
REGENXBIO Reports First Quarter 2024 Financial Results and Recent Operational Highlights
Company remains on track for its first BLA filing in 2024 and is accelerating progress toward pivotal trial initiation for Duchenne (H2 2024) and diabetic retinopathy (H1 2025) Dose level 2 selected as pivotal dose for RGX-202 treatment of Duchenne New positive interim efficacy and safety data announced for second boy at DL2 AFFINITY DUCHENNE® trial expansion phase is underway with third and fourth boys dosed at DL2 End-of-Phase II meeting with FDA planned for early Q3 and pivotal trial initiation anticipated in late Q3 to early Q4 2024 Positive interim results from ALTITUDE® trial for diabetic retinopathy support plans for anticipated End-of-Phase II meeting with FDA in Q1 2025 $381 million in cash, cash equivalents and marketable securities as of March 31, 2024, expected to fund operational runway into 2026 Conference call Wednesday, May 8, at 4:30 p.m. ET ROCKVILLE, Md.
REGENXBIO Reports First Quarter 2024 Financial Results and Recent Operational Highlights
Company remains on track for its first BLA filing in 2024 and is accelerating progress toward pivotal trial initiation for Duchenne (H2 2024) and diabetic retinopathy (H1 2025) Dose level 2 selected as pivotal dose for RGX-202 treatment of Duchenne New positive interim efficacy and safety data announced for second boy at DL2 AFFINITY DUCHENNE® trial expansion phase is underway with third and fourth boys dosed at DL2 End-of-Phase II meeting with FDA planned for early Q3 and pivotal trial initiation anticipated in late Q3 to early Q4 2024 Positive interim results from ALTITUDE® trial for diabetic retinopathy support plans for anticipated End-of-Phase II meeting with FDA in Q1 2025 $381 million in cash, cash equivalents and marketable securities as of March 31, 2024, expected to fund operational runway into 2026 Conference call Wednesday, May 8, at 4:30 p.m. ET ROCKVILLE, Md.
05/01 07:05 EST - prnewswire.com
REGENXBIO to Host Conference Call on May 8 to Discuss First Quarter 2024 Financial Results and Recent Operational Highlights
ROCKVILLE, Md. , May 1, 2024 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that it will host a conference call on Wednesday, May 8, 2024, at 4:30 p.m.
REGENXBIO to Host Conference Call on May 8 to Discuss First Quarter 2024 Financial Results and Recent Operational Highlights
ROCKVILLE, Md. , May 1, 2024 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that it will host a conference call on Wednesday, May 8, 2024, at 4:30 p.m.
04/24 07:05 EST - prnewswire.com
REGENXBIO to Participate in Chardan's 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit
ROCKVILLE, Md. , April 24, 2024 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it will participate in Chardan's 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit on Monday, April 29, 2024.
REGENXBIO to Participate in Chardan's 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit
ROCKVILLE, Md. , April 24, 2024 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it will participate in Chardan's 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit on Monday, April 29, 2024.
03/28 07:05 EST - prnewswire.com
REGENXBIO Announces Lancet Publication of Phase I/IIa Study Evaluating ABBV-RGX-314 as a One-Time Gene Therapy for Wet AMD
A single ABBV-RGX-314 gene therapy treatment has the potential to become a new standard-of-care option among anti-VEGF treatments by sustaining vision health long term and overcoming the clinical challenges of managing wet AMD due to the treatment burden of chronic anti-VEGF injections Patients who received therapeutic doses resulted in stable or improved vision and retinal anatomy up to 2 years Additional long-term follow-up data has demonstrated durable treatment effect, with stable or improved vision, up to 4 years Enrollment is on track in pivotal trials of ABBV-RGX-314 in wet AMD that are expected to support global regulatory submissions in late 2025 through the first half of 2026 ROCKVILLE, Md. , March 28, 2024 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced the publication of results from the Phase I/IIa trial evaluating the safety and tolerability of a single dose of subretinal ABBV-RGX-314 for the treatment of wet age-related macular degeneration (wet AMD).
REGENXBIO Announces Lancet Publication of Phase I/IIa Study Evaluating ABBV-RGX-314 as a One-Time Gene Therapy for Wet AMD
A single ABBV-RGX-314 gene therapy treatment has the potential to become a new standard-of-care option among anti-VEGF treatments by sustaining vision health long term and overcoming the clinical challenges of managing wet AMD due to the treatment burden of chronic anti-VEGF injections Patients who received therapeutic doses resulted in stable or improved vision and retinal anatomy up to 2 years Additional long-term follow-up data has demonstrated durable treatment effect, with stable or improved vision, up to 4 years Enrollment is on track in pivotal trials of ABBV-RGX-314 in wet AMD that are expected to support global regulatory submissions in late 2025 through the first half of 2026 ROCKVILLE, Md. , March 28, 2024 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced the publication of results from the Phase I/IIa trial evaluating the safety and tolerability of a single dose of subretinal ABBV-RGX-314 for the treatment of wet age-related macular degeneration (wet AMD).
03/27 16:05 EST - prnewswire.com
REGENXBIO to Participate in Cantor Fitzgerald's Virtual DMD and Other Dystrophy Days
ROCKVILLE, Md. , March 27, 2024 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it will participate in Cantor Fitzgerald's Virtual DMD and Other Dystrophy Days on Wednesday, April 3, 2024.
REGENXBIO to Participate in Cantor Fitzgerald's Virtual DMD and Other Dystrophy Days
ROCKVILLE, Md. , March 27, 2024 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it will participate in Cantor Fitzgerald's Virtual DMD and Other Dystrophy Days on Wednesday, April 3, 2024.
03/11 11:53 EST - seekingalpha.com
Regenxbio: DMD Program Lends Additional Credibility To NAV Technology Platform
Positive interim results released from phase 1/2 AFFINITY study, using RGX-202 for the treatment of patients with Duchenne Muscular Dystrophy. Functional and strength data from the phase 1/2 AFFINITY study, using RGX-202 for the treatment of patients with Duchenne Muscular Dystrophy, expected in the 2nd half of 2024. The Duchenne Muscular Dystrophy Treatment Market size is estimated to reach $4.32 billion by 2029.
Regenxbio: DMD Program Lends Additional Credibility To NAV Technology Platform
Positive interim results released from phase 1/2 AFFINITY study, using RGX-202 for the treatment of patients with Duchenne Muscular Dystrophy. Functional and strength data from the phase 1/2 AFFINITY study, using RGX-202 for the treatment of patients with Duchenne Muscular Dystrophy, expected in the 2nd half of 2024. The Duchenne Muscular Dystrophy Treatment Market size is estimated to reach $4.32 billion by 2029.
03/06 23:20 EST - prnewswire.com
REGENXBIO Announces Pricing of Upsized Public Offering of Common Stock and Pre-funded Warrants
ROCKVILLE, Md. , March 6, 2024 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy, today announced the pricing of an underwritten upsized public offering of 4,565,260 shares of its common stock at the price of $23.00 per share and 1,521,740 pre-funded warrants at a price of $22.9999 per warrant, in each case before underwriting discounts and commissions.
REGENXBIO Announces Pricing of Upsized Public Offering of Common Stock and Pre-funded Warrants
ROCKVILLE, Md. , March 6, 2024 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy, today announced the pricing of an underwritten upsized public offering of 4,565,260 shares of its common stock at the price of $23.00 per share and 1,521,740 pre-funded warrants at a price of $22.9999 per warrant, in each case before underwriting discounts and commissions.
03/06 16:10 EST - prnewswire.com
REGENXBIO Announces Proposed Public Offering of Common Stock
ROCKVILLE, Md. , March 6, 2024 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that it intends to offer and sell, subject to market conditions, $125,000,000 of its common stock in an underwritten public offering.
REGENXBIO Announces Proposed Public Offering of Common Stock
ROCKVILLE, Md. , March 6, 2024 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that it intends to offer and sell, subject to market conditions, $125,000,000 of its common stock in an underwritten public offering.
03/06 12:36 EST - zacks.com
REGENXBIO (RGNX) Soars 15% on Interim Data From DMD Study
Data from an early-stage study shows that treatment with REGENXBIO's (RGNX) investigational Duchenne therapy RGX-202 demonstrates early evidence of strength and motor function improvement.
REGENXBIO (RGNX) Soars 15% on Interim Data From DMD Study
Data from an early-stage study shows that treatment with REGENXBIO's (RGNX) investigational Duchenne therapy RGX-202 demonstrates early evidence of strength and motor function improvement.